JP2007515469A - Ｃｄ４０抗体製剤および方法 - Google Patents

Ｃｄ４０抗体製剤および方法 Download PDF

Info

Publication number
JP2007515469A
JP2007515469A JP2006546357A JP2006546357A JP2007515469A JP 2007515469 A JP2007515469 A JP 2007515469A JP 2006546357 A JP2006546357 A JP 2006546357A JP 2006546357 A JP2006546357 A JP 2006546357A JP 2007515469 A JP2007515469 A JP 2007515469A
Authority
JP
Japan
Prior art keywords
antibody
tumor
antibodies
patient
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007515469A5 (enExample
Inventor
ヴァーヘ・ベディアン
ジョン・ダニエル・クスマーノウ
ロナルド・ポール・グラデュー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34738672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007515469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2007515469A publication Critical patent/JP2007515469A/ja
Publication of JP2007515469A5 publication Critical patent/JP2007515469A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006546357A 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法 Pending JP2007515469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53163903P 2003-12-22 2003-12-22
PCT/IB2004/004103 WO2005063289A1 (en) 2003-12-22 2004-12-09 Cd40 antibody formulation and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011100868A Division JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法

Publications (2)

Publication Number Publication Date
JP2007515469A true JP2007515469A (ja) 2007-06-14
JP2007515469A5 JP2007515469A5 (enExample) 2008-01-31

Family

ID=34738672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006546357A Pending JP2007515469A (ja) 2003-12-22 2004-12-09 Ｃｄ４０抗体製剤および方法
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011100868A Expired - Fee Related JP5634321B2 (ja) 2003-12-22 2011-04-28 Ｃｄ４０抗体製剤および方法
JP2014121342A Pending JP2014205692A (ja) 2003-12-22 2014-06-12 Ｃｄ４０抗体製剤および方法

Country Status (20)

Country Link
US (4) US20050136055A1 (enExample)
EP (3) EP3081933A1 (enExample)
JP (3) JP2007515469A (enExample)
KR (2) KR100847944B1 (enExample)
CN (2) CN102552905A (enExample)
AU (1) AU2004308749B2 (enExample)
BR (1) BRPI0418029B8 (enExample)
CA (2) CA2549652C (enExample)
DK (1) DK2218461T3 (enExample)
ES (1) ES2580002T3 (enExample)
HU (1) HUE027717T2 (enExample)
IL (2) IL175540A (enExample)
NO (1) NO343797B1 (enExample)
NZ (2) NZ583179A (enExample)
PL (1) PL2218461T3 (enExample)
RU (1) RU2355421C2 (enExample)
SI (1) SI2218461T1 (enExample)
TW (1) TWI359671B (enExample)
WO (1) WO2005063289A1 (enExample)
ZA (1) ZA200603804B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
JP2022503961A (ja) * 2018-09-28 2022-01-12 リビジェン バイオファーマ カンパニー リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
JP2022513671A (ja) * 2018-11-30 2022-02-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｃｄ４０抗体医薬品組成物およびその使用
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
MX2008007140A (es) * 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
JP2012501323A (ja) * 2008-08-29 2012-01-19 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
US9561214B2 (en) * 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
WO2017214452A1 (en) 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US20200055947A1 (en) 2016-11-04 2020-02-20 Memorial Sloan Kettering Cancer Center Bi-specific activators for tumor therapy
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP3632933A4 (en) 2017-06-01 2021-03-03 Seoul National University R & DB Foundation Novel anti-cd40 antibodies and use thereof
EP3418302A1 (en) * 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Administration routes for immune agonists
CN112512572B (zh) * 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN112996818B (zh) * 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
US12435150B2 (en) 2019-01-11 2025-10-07 Novartis Ag Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4048701A4 (en) 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
EP4161968A4 (en) * 2020-06-04 2024-06-26 Selvax Pty Ltd. AGONISTIC ANTI-CD40 ANTIBODIES
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
SE8701004D0 (sv) 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
JPH03204821A (ja) * 1989-12-28 1991-09-06 Green Cross Corp:The モノクローナル抗体含有水溶液の加熱処理方法
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
FI961285L (fi) * 1993-10-01 1996-03-20 Immunex Corp CD40:n vasta-aineita
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1181054A1 (en) * 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
US6358670B1 (en) * 1999-12-28 2002-03-19 Electron Vision Corporation Enhancement of photoresist plasma etch resistance via electron beam surface cure
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
EP1283722A1 (en) * 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) * 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
WO2002028481A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
US7771951B2 (en) * 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US20080009439A1 (en) * 2002-11-05 2008-01-10 Alsobrook John P Compositions and Methods of Use for a Fibroblast Growth Factor
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040170A2 (en) * 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
JP2005508176A (ja) * 2001-11-09 2005-03-31 ファイザー・プロダクツ・インク Ｃｄ４０に対する抗体

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
JP2022503961A (ja) * 2018-09-28 2022-01-12 リビジェン バイオファーマ カンパニー リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
JP7626698B2 (ja) 2018-09-28 2025-02-04 リビジェン バイオファーマ ホールディングス リミテッド 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
JP2022513671A (ja) * 2018-11-30 2022-02-09 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Ｃｄ４０抗体医薬品組成物およびその使用
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法

Also Published As

Publication number Publication date
IL175540A (en) 2011-10-31
DK2218461T3 (en) 2016-05-17
IL175540A0 (en) 2006-09-05
KR20070012626A (ko) 2007-01-26
NO343797B1 (no) 2019-06-11
TWI359671B (en) 2012-03-11
CA2549652A1 (en) 2005-07-14
EP2218461A1 (en) 2010-08-18
IL201409A0 (en) 2010-05-31
CN102552905A (zh) 2012-07-11
CA2549652C (en) 2013-11-12
AU2004308749A1 (en) 2005-07-14
WO2005063289A1 (en) 2005-07-14
US20120263732A1 (en) 2012-10-18
JP2014205692A (ja) 2014-10-30
NZ583179A (en) 2011-06-30
KR20080023766A (ko) 2008-03-14
BRPI0418029B8 (pt) 2021-05-25
RU2355421C2 (ru) 2009-05-20
TW200521142A (en) 2005-07-01
CA2704300A1 (en) 2005-07-14
HUE027717T2 (en) 2016-10-28
EP1706143A1 (en) 2006-10-04
CN1897971A (zh) 2007-01-17
BRPI0418029A (pt) 2007-04-17
NZ547162A (en) 2010-03-26
US20050136055A1 (en) 2005-06-23
JP5634321B2 (ja) 2014-12-03
NO20063373L (no) 2006-09-21
AU2004308749B2 (en) 2010-10-28
BRPI0418029B1 (pt) 2018-12-26
ES2580002T3 (es) 2016-08-18
JP2011184446A (ja) 2011-09-22
US20110104182A1 (en) 2011-05-05
EP2218461B1 (en) 2016-04-20
EP3081933A1 (en) 2016-10-19
RU2006120950A (ru) 2008-01-27
ZA200603804B (en) 2007-09-26
US20090311254A1 (en) 2009-12-17
KR100847944B1 (ko) 2008-07-22
SI2218461T1 (sl) 2016-08-31
PL2218461T3 (pl) 2016-09-30

Similar Documents

Publication Publication Date Title
JP5634321B2 (ja) Ｃｄ４０抗体製剤および方法
JP2013518123A (ja) Ｄｌｌ４アンタゴニストによる糖尿病の治療法
JP2025013608A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
CN115956088A (zh) 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
TW202313682A (zh) 抗icos抗體之用途
EP4396213A1 (en) Method of treating diseases with anti-pd-l1/il-10 fusion proteins
WO2023146394A1 (en) Combination therapy for the treatment of cancer
TW201902462A (zh) 用於免疫促效劑之新穎投與途徑
TW201713346A (zh) 調控免疫反應之方法及抗體
CN112439060B (zh) Pd-l1免疫疗法的新用途
HK1172823A (en) Cd40 antibody formulation and methods
MXPA06006153A (en) Cd40 antibody formulation and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071206

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081110

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110725